GO:0030332 cyclin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030332 cyclin binding is a molecular function describing the selective, non-covalent association of a protein with a cyclin, the regulatory subunit whose abundance rises and falls across the cell cycle.
• Cyclin binding is the molecular prerequisite for activation of cyclin-dependent kinases (CDKs), which phosphorylate substrates that drive G1/S and G2/M transitions.
• Binding affinity differs substantially among CDK-cyclin pairs, providing a biochemical basis for phase-specific substrate selection.
• Short linear motifs, including the RxL cyclin-binding motif of p21CIP1, mediate many cyclin-docking interactions and are essential for p21 function.
• High-throughput motif profiling has revealed that cyclin docking determinants are more complex than a single consensus sequence.
• Non-canonical cyclin partners such as cyclin Y regulate processes beyond the cell cycle, including actin dynamics and neuronal spine plasticity.
Description
Cyclin binding (GO:0030332) is the molecular function of selectively and non-covalently interacting with a cyclin protein. Cyclins are defined by their strongly cell-cycle-regulated abundance: their levels rise steadily through interphase and fall abruptly at mitosis, and when they reach a threshold they are thought to drive cells into G2 phase and mitosis. Because cyclins have no intrinsic catalytic activity, their biological output depends entirely on binding to partner proteins, most prominently cyclin-dependent kinases (CDKs). Cyclin binding therefore sits at the mechanistic center of cell-cycle control and of essentially every process that is timed by CDK activity. For researchers, GO:0030332 is a practical annotation target. It captures the interaction step itself, distinct from downstream phosphorylation, and it can be assayed by co-immunoprecipitation, affinity measurement, peptide arrays, and structural methods. The affinity of a given CDK-cyclin pair is not uniform; systematic comparisons show measurable differences that help explain why particular complexes act in particular cell-cycle phases. In parallel, short linear docking motifs such as the RxL motif of p21CIP1 provide a modular, genetically tractable route to perturb cyclin binding without deleting the cyclin itself. Beyond the canonical cell cycle, cyclin binding underlies specialized signaling. Cyclin Y binds actin-associated machinery and regulates spine plasticity through the cofilin-actin pathway, and its phosphorylation-dependent interaction with 14-3-3 proteins controls activation of PCTAIRE-1/CDK16. This breadth makes GO:0030332 relevant to cancer biology, neurobiology, and the design of targeted chemical probes.
cyclin binding At A Glance
| GO ID | GO:0030332 |
|---|---|
| GO term | cyclin binding |
| Ontology | molecular_function |
| Synonym | None listed in QuickGO |
| Major function | Selective, non-covalent association with a cyclin protein, enabling cyclin-dependent kinase activation and phase-specific substrate targeting |
| Definition source concept | Cyclins fluctuate markedly across the cell cycle, rising until mitosis and falling abruptly; threshold cyclin levels are thought to drive G2 phase and mitosis |
| Representative binders | CDKs, p21CIP1-family CDK inhibitors, PCTAIRE-1/CDK16, actin-associated partners of cyclin Y |
| Experimental readouts | Co-immunoprecipitation, affinity determination, peptide motif arrays, structural modeling |
| Disease relevance | Cell-cycle dysregulation in cancer, neuronal plasticity pathways, and chemical probe development |
What Is GO:0030332?
In plain terms, GO:0030332 cyclin binding means a protein physically grabs onto a cyclin. Formally, it is the binding to cyclins, proteins whose levels in a cell vary markedly during the cell cycle, rising steadily until mitosis and then falling abruptly to zero; as cyclins reach a threshold level they are thought to drive cells into G2 phase and thus to mitosis. The term describes the recognition event itself, not any catalytic consequence, and it applies to any protein that associates with a cyclin, including CDKs, CDK inhibitors such as p21CIP1, and non-canonical partners such as cyclin Y effectors.
Why Is cyclin binding Important in Cell Biology?
Cyclin binding is important because it converts an oscillating regulatory protein into a functional enzyme complex. Without cyclin binding, CDKs lack the conformational and substrate-recognition changes needed for activity, so the timing of phosphorylation events that gate DNA replication and mitosis depends directly on which cyclin binds which kinase and when. Because affinity and motif preferences differ among CDK-cyclin pairs, cyclin binding also provides specificity, helping explain why distinct complexes act in distinct cell-cycle phases. Perturbing cyclin binding, for example by mutating the RxL motif of p21CIP1, is sufficient to impair p21 function, showing that this interaction is not incidental but essential. Finally, cyclin-binding interfaces are druggable in principle, and the broader success of small-molecule protein-protein interaction antagonists supports interest in this target class.
• Provides the activation step for CDKs, the core engines of cell-cycle progression.
• Confers phase specificity, since different CDK-cyclin pairs show different binding affinities.
• Is required for the function of CDK inhibitors such as p21CIP1 through dedicated cyclin-binding motifs.
• Can be dissected at motif resolution using high-throughput docking interaction assays.
• Extends beyond the cell cycle, as cyclin Y regulates actin dynamics and spine plasticity.
• Is regulated by phosphorylation and 14-3-3 binding in the PCTAIRE-1/CDK16 pathway.
• Represents a protein-protein interaction interface amenable to small-molecule intervention.
• Offers a genetically tractable handle for CRISPR knockout, point mutation, and knock-in studies of cell-cycle control.
Molecular Mechanism of cyclin binding
Cyclin recognition and docking
In simple terms: A partner protein finds and holds onto a cyclin using a short docking patch.
Cyclin binding begins with recognition of a cyclin surface by a complementary region on the partner protein. Many interactions are mediated by short linear motifs, and the RxL cyclin-binding motif of p21CIP1 is a classic example whose integrity is essential for p21 function. High-throughput investigation of cyclin docking interactions has shown that motif binding determinants are more complex than a single consensus sequence, implying that multiple sequence features contribute to selectivity.
Complex assembly and CDK activation
In simple terms: Once the cyclin is bound, the kinase partner switches on.
Cyclin binding is the prerequisite for assembly of active cyclin-CDK complexes. Binding modalities and phase-specific regulation of cyclin/CDK complexes have been characterized, indicating that the interaction is tuned to the cell-cycle stage in which the complex acts. Because cyclins themselves are not catalytic, the functional consequence of binding is activation of the associated kinase and subsequent substrate phosphorylation.
Affinity and specificity determinants
In simple terms: Different cyclin-kinase pairs stick together more or less tightly.
Systematic comparison of cell-cycle CDK and cyclin pairs has revealed differences in binding affinity among them. These affinity differences provide a biochemical basis for preferential pairing and for phase-specific complex formation, complementing the motif-level determinants identified by high-throughput docking studies.
Regulation by phosphorylation and 14-3-3
In simple terms: Chemical tags and helper proteins can switch cyclin binding on or off.
Cyclin binding is not constitutive. In the PCTAIRE-1/CDK16 pathway, cyclin Y phosphorylation and 14-3-3 binding are required for activation, illustrating how post-translational modification and adaptor proteins gate the interaction. This layer of regulation allows cyclin binding to be coupled to upstream signals rather than solely to cyclin abundance.
Non-canonical cyclin binding functions
In simple terms: Some cyclins bind proteins that have nothing to do with driving the cell cycle.
Cyclin Y acts as an actin-binding protein and regulates spine plasticity through the cofilin-actin pathway, demonstrating that cyclin binding can serve cytoskeletal and neuronal functions. Such non-canonical interactions broaden the functional scope of GO:0030332 beyond canonical CDK activation.
Key Genes Involved in GO:0030332 cyclin binding
The following genes and proteins are representative binders or partners relevant to cyclin binding (GO:0030332), based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK1 | Catalytic partner of mitotic cyclins | Core cyclin-binding kinase for G2/M studies |
| CDK2 | Catalytic partner of G1/S cyclins | Affinity differences among cyclin pairs |
| CDK4 | Catalytic partner of D-type cyclins | Phase-specific complex regulation |
| CDK6 | Catalytic partner of D-type cyclins | Phase-specific complex regulation |
| CCNA2 | Cyclin A, S/G2 regulator | Cyclin partner in affinity comparisons |
| CCNB1 | Cyclin B, mitotic regulator | Cyclin partner in affinity comparisons |
| CCND1 | Cyclin D, G1 regulator | Cyclin partner in affinity comparisons |
| CCNE1 | Cyclin E, G1/S regulator | Cyclin partner in affinity comparisons |
| CCNY | Cyclin Y, non-canonical cyclin | Actin binding and spine plasticity; PCTAIRE-1 activation |
| CDK16 | PCTAIRE-1 kinase | Activated by cyclin Y phosphorylation and 14-3-3 binding |
| CDKN1A | p21CIP1 CDK inhibitor | RxL cyclin-binding motif essential for function |
| MDM2 | p53 pathway regulator | Target of small-molecule antagonists, illustrating PPI druggability |
| TP53 | p53 tumor suppressor | Pathway activated by MDM2 antagonists |
| YWHAB | 14-3-3 family adaptor | 14-3-3 binding required for cyclin Y-dependent CDK16 activation |
| CFL1 | Cofilin, actin dynamics regulator | Effector in cyclin Y cofilin-actin pathway |
| ACTB | Actin cytoskeleton component | Context for cyclin Y actin-binding function |
| CDKN1B | p27Kip1 CDK inhibitor | Family member sharing cyclin-binding inhibitor logic |
How Is cyclin binding Regulated?
Cyclin binding is regulated at several levels. The abundance of the cyclin itself oscillates markedly across the cell cycle, rising until mitosis and falling abruptly, and threshold cyclin levels are thought to drive cells into G2 phase and mitosis. Beyond abundance, the interaction is tuned by phase-specific mechanisms that determine which cyclin-CDK complexes assemble when. Post-translational modification adds another layer: cyclin Y phosphorylation and 14-3-3 binding are required for activation of PCTAIRE-1/CDK16, showing that adaptor binding can gate cyclin-dependent signaling. Finally, inhibitor proteins such as p21CIP1 use dedicated cyclin-binding motifs to engage and modulate cyclin-CDK complexes, and disruption of these motifs impairs inhibitor function.
cyclin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDKN1A | Loss of CDK inhibition and cell-cycle restraint | RxL motif point-mutation knock-in to disrupt cyclin binding |
| CCNY | Neuronal plasticity and cytoskeletal regulation | Knockout or tagged knock-in in neuronal cell models |
| CDK16 | PCTAIRE-1 signaling dependent on cyclin Y and 14-3-3 | Phospho-mutant and 14-3-3-binding mutant knock-in |
| MDM2 | p53 pathway suppression in tumors | Overexpression and small-molecule antagonist studies |
| CDK2 | Cell-cycle progression and affinity-dependent complex formation | Knockout and affinity-variant knock-in comparisons |
Cancer and cell-cycle dysregulation
Because cyclin binding gates CDK activation and phase-specific substrate phosphorylation, alterations that change which cyclin binds which kinase can perturb cell-cycle timing. The p53 pathway, a central barrier to uncontrolled proliferation, can be activated pharmacologically by small-molecule antagonists of MDM2, demonstrating that protein-protein interaction interfaces in this network are actionable drug targets. Cyclin-binding motifs in inhibitors such as p21CIP1 are essential for their function, so their disruption is expected to weaken cell-cycle restraint.
Neuronal plasticity and cytoskeletal signaling
Cyclin Y is a non-canonical cyclin that acts as an actin-binding protein and regulates spine plasticity through the cofilin-actin pathway. Its phosphorylation- and 14-3-3-binding-dependent activation of PCTAIRE-1/CDK16 links cyclin binding to neuronal signaling mechanisms. These findings indicate that cyclin-binding proteins can contribute to nervous-system biology independently of canonical cell-cycle control.
Therapeutic targeting of cyclin-binding interfaces
Cyclin-binding surfaces are protein-protein interaction interfaces, a class that has proven tractable to small-molecule intervention, as shown by MDM2 antagonists that activate p53 in vivo. Detailed understanding of binding modalities and affinity differences among cyclin-CDK pairs provides a rational basis for designing or interpreting such interventions.
From cyclin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a cyclin-binding motif required for inhibitor function? | Point mutation of the RxL motif in CDKN1A |
| Which CDK-cyclin pairs form preferentially? | Knockout of individual cyclins with affinity measurement of remaining pairs |
| Does cyclin Y phosphorylation control CDK16 activation? | Phospho-site point mutation and 14-3-3-binding mutant knock-in |
| Where and when does a cyclin partner localize? | Endogenous tagged knock-in for imaging |
| Does increased cyclin abundance drive phase transitions? | Overexpression of a specific cyclin |
| Can a cyclin-binding interface be drugged? | Overexpression models combined with small-molecule PPI antagonists |
How to Study the cyclin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical association between a cyclin and a partner | Confirming endogenous cyclin binding |
| Affinity determination | Strength of binding between CDK and cyclin pairs | Comparing phase-specific complexes |
| High-throughput motif profiling | Sequence determinants of cyclin docking | Mapping binding motifs at scale |
| Structural and computational modeling | Interface geometry and binding modality | Explaining phase-specific regulation |
| Site-directed mutagenesis | Requirement of a motif for function | Testing RxL motif necessity in p21CIP1 |
| Phospho-mutant analysis | Role of phosphorylation in complex activation | Cyclin Y-dependent CDK16 activation |
| Small-molecule PPI perturbation | Druggability of a binding interface | Activating p53 via MDM2 antagonism |
| Imaging of tagged proteins | Localization of cyclin-binding partners | Studying cyclin Y in spine plasticity |
Binding and affinity assays
Direct measurement of cyclin binding is central to studying GO:0030332. Comparative affinity determination across cell-cycle CDK and cyclin pairs has been used to quantify differences among complexes. Co-immunoprecipitation and related interaction assays complement these measurements by detecting endogenous complex formation.
High-throughput motif profiling
High-throughput investigation of cyclin docking interactions enables systematic mapping of motif binding determinants, revealing complexity beyond simple consensus sequences. Such approaches are well suited to defining which residues in a candidate binder are required for cyclin recognition.
Structural and computational analysis
Binding modalities and phase-specific regulation of cyclin/CDK complexes have been examined using combined structural and computational approaches. These methods help rationalize how a given interface achieves selectivity and how mutations might alter it.
Functional perturbation and pharmacology
Functional tests of cyclin binding rely on perturbing the interaction and scoring downstream phenotypes. Mutation of the p21CIP1 cyclin-binding motif impairs its function, providing a template for loss-of-binding experiments. Small-molecule antagonists of protein-protein interactions, such as MDM2 antagonists that activate p53 in vivo, illustrate how chemical perturbation can complement genetic approaches.
How CRISPR Can Be Used to Study GO:0030332 cyclin binding
Knockout
CRISPR knockout of a cyclin or of a cyclin-binding partner removes the interaction entirely and reveals its contribution to complex formation and downstream phenotypes. Because different CDK-cyclin pairs show different affinities, knocking out one cyclin allows the remaining pairs to be measured and compared. Knockout of non-canonical cyclins such as cyclin Y can be used to test actin-related and plasticity phenotypes.
Point Mutation
Point mutation is the most precise way to test whether a specific residue mediates cyclin binding. The RxL cyclin-binding motif of p21CIP1 is essential for its function, so introducing motif-disrupting substitutions provides a clean loss-of-binding allele. Similarly, phospho-site mutations can test the requirement for cyclin Y phosphorylation in PCTAIRE-1/CDK16 activation.
Knock-in
Knock-in of tagged or affinity-variant alleles allows cyclin binding to be studied in the endogenous context. Tagged knock-in supports localization and interaction studies of partners such as cyclin Y, while knock-in of altered affinity variants can test whether binding strength, rather than binding per se, determines phase-specific function.
Overexpression
Overexpression of a cyclin or of a cyclin-binding protein raises complex levels and can reveal threshold effects, consistent with the idea that cyclins drive progression once they reach a threshold. Overexpression models also provide a background for testing small-molecule protein-protein interaction antagonists that target cyclin-binding interfaces.
How EDITGENE Supports cyclin binding Research
Researchers studying cyclin binding-related genes often need to determine whether a candidate gene is causally involved in complex assembly, phase-specific regulation, or downstream signaling. Establishing causality typically requires precise genetic models in which a cyclin, a CDK, or a docking motif is removed, altered, or tagged without confounding off-target effects. EDITGENE provides the full range of CRISPR-engineered cell models needed to move from correlation to mechanism in cyclin-binding research.
Contact EDITGENE today to design your custom CRISPR model for cyclin binding research.
Frequently Asked Questions About cyclin binding
What is GO:0030332 cyclin binding?
GO:0030332 is a molecular function term describing binding to cyclins, proteins whose levels vary markedly during the cell cycle, rising until mitosis and then falling abruptly; threshold cyclin levels are thought to drive cells into G2 phase and mitosis.
What genes are involved in cyclin binding?
Representative genes include CDK1, CDK2, CDK4, CDK6, CCNA2, CCNB1, CCND1, CCNE1, CCNY, CDK16, CDKN1A, and YWHAB, based on studies of cyclin-CDK complexes, p21CIP1 motifs, and cyclin Y signaling.
Why is cyclin binding important for the cell cycle?
Cyclins lack catalytic activity, so their biological output depends on binding to kinases such as CDKs; this binding is required for complex activation and for phase-specific substrate phosphorylation.
What is the RxL cyclin-binding motif?
The RxL motif is a short linear sequence in p21CIP1 that mediates cyclin binding; mutating it impairs p21 function, showing the motif is essential.
Do all CDK-cyclin pairs bind with the same affinity?
No. Systematic comparison of cell-cycle CDK and cyclin pairs has revealed differences in binding affinity among them.
How is cyclin binding regulated?
It is regulated by cyclin abundance across the cell cycle, by phase-specific assembly mechanisms, and by post-translational events such as cyclin Y phosphorylation and 14-3-3 binding in the PCTAIRE-1/CDK16 pathway.
Is cyclin binding only about the cell cycle?
No. Cyclin Y acts as an actin-binding protein and regulates spine plasticity through the cofilin-actin pathway, showing non-canonical functions.
Can cyclin-binding interfaces be targeted by drugs?
Protein-protein interaction interfaces can be druggable; MDM2 antagonists activate the p53 pathway in vivo, illustrating the principle for this target class.
What methods are used to study cyclin binding?
Common approaches include co-immunoprecipitation, affinity determination, high-throughput motif profiling, structural and computational analysis, and functional mutagenesis.
How can CRISPR help study cyclin binding?
CRISPR knockout removes a cyclin or partner, point mutation disrupts a docking motif such as RxL, knock-in enables tagged or affinity-variant alleles, and overexpression tests threshold effects.
Conclusion
Cyclin binding (GO:0030332) is a compact molecular function with outsized consequences: it converts oscillating cyclin abundance into activated kinase complexes that time the cell cycle, and it extends into non-canonical roles such as actin regulation and neuronal plasticity. Its determinants range from short linear motifs like the RxL sequence of p21CIP1 to affinity differences among CDK-cyclin pairs and phosphorylation-dependent adaptor binding. Because these interfaces are genetically and chemically tractable, cyclin binding remains a productive focus for mechanistic and translational research.
References
- 1. Bergman MT et al.. 2024. Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle.. J Phys Chem B 128(39):9315-9326 PMID: 39314090
- 2. Örd M et al.. 2025. High-throughput investigation of cyclin docking interactions reveals the complexity of motif binding determinants.. Nat Commun 16(1):7622 PMID: 40817109
- 3. Vassilev LT et al.. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.. Science 303(5659):844-8 PMID: 14704432
- 4. Putta S et al.. 2025. Differences in Binding Affinity Among Cell-cycle CDK and Cyclin Pairs.. J Mol Biol 437(5):168952 PMID: 39826708
- 5. Chen J et al.. 1996. Cyclin-binding motifs are essential for the function of p21CIP1.. Mol Cell Biol 16(9):4673-82 PMID: 8756624
- 6. Ball KL. 1997. p21: structure and functions associated with cyclin-CDK binding.. Prog Cell Cycle Res 3:125-34 PMID: 9552411
- 7. Hwang H et al.. 2021. Cyclin Y, a novel actin-binding protein, regulates spine plasticity through the cofilin-actin pathway.. Prog Neurobiol 198:101915 PMID: 32966834
- 8. Shehata SN et al.. 2015. Cyclin Y phosphorylation- and 14-3-3-binding-dependent activation of PCTAIRE-1/CDK16.. Biochem J 469(3):409-20 PMID: 26205494
